Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$12.78 ▼ -0.15
(-1.16%)
MKT CAP: $706.0M • VOL: 848.9K
52W L $7 52W H $17
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$11
MEDIAN
$14
MEAN
$15
HIGH
$17
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE FDMT TAPE
FDMT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $15.46 | $14.70 | 2025-02-14 | $11.63 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $16.10 | $15.08 | 2025-02-06 | $12.01 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $14.57 | $14.06 | 2025-01-29 | $12.27 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $13.04 | — | 2025-01-17 | $12.52 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $11.25 | $12.14 | 2025-01-09 | $11.37 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $15.21 | $13.29 | 2024-12-18 | $11.12 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $12.40 | $12.91 | 2024-12-04 | $11.89 | -4.3% | 48% | C |